Immunotherapy for colorectal cancer: where are we heading?

Expert Opinion on Biological Therapy

Volumn 17, Issue 6, 2017, Pages 709-721

  Basile, Debora ^a   Garattini, Silvio Ken ^a   Bonotto, Marta ^a   Ongaro, Elena ^a   Casagrande, Mariaelena ^a   Cattaneo, Monica ^a   Fanotto, Valentina ^a   De Carlo, Elisa ^a   Loupakis, Fotios ^c   Urbano, Federica ^b,c   Negri, Francesca V ^d   Pella, Nicoletta ^a   Russano, Marco ^e   Brunetti, Oronzo ^f   Scartozzi, Mario ^g   Santini, Daniele ^e   Silvestris, Nicola ^f   Casadei Gardini, Andrea ^h   Puzzoni, Marco ^g   Calvetti, Lorenzo ⁱ   Cardarelli, Nadia ⁱ   Aprile, Giuseppe ^a,i   more..

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g UNIVERSITY OF CAGLIARI   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ San Bortolo General Hospital   (Italy)

Author keywords

atezolizumab; colorectal cancer; Immunotherapy; MSI; PD L1; pembrolizumab

Indexed keywords

CD4 ANTIGEN; IMMUNOMODULATING AGENT; IPILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL; NATURAL KILLER T CELL; NONHUMAN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; TUMOR MICROENVIRONMENT; COLORECTAL NEOPLASMS; COMBINATION DRUG THERAPY; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROGNOSIS; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CTLA-4 ANTIGEN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PROGNOSIS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85019084692     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2017.1315405     Document Type: Review

References (97)

1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics,2017. CA Cancer J Clin. 2017. Epub ahead of print.
2. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66:683–691.
3. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–1315.
4. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer:A systematic review and meta-analysis. Acta Oncol. 2014;53:852–864.
5. Lim B, Kim J-H, Kim M, et al. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol. 2016;22:1190–1201.
6. Song J-L, Chen C, Yuan J-P, et al. Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med. 2016;5(12):3475–3488.
7. Pietrantonio F, Vernieri C, Siravegna G, et al. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017.
8. Ogino S, Nishihara R, VanderWeele TJ, et al. Review article:the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiol Camb Mass. 2016;27:602–611.
9. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–1356.• This experts’ consensus on the molecular subtype of colorectal adenocarcinomas leads to novel approaches and personalized treatments.
10. Zhang C-M, Lv J-F, Gong L, et al. Role of deficient mismatch repair in the personalized management of colorectal cancer. Int J Environ Res Public Health. 2016;13(9):892.
11. Markman JL, Shiao SL., Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208–223.
12. Parcesepe P, Giordano G, Laudanna C, et al. Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer. Gastroenterol Res Pract. 2016;2016:6261721.
13. Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore:a worldwide task force. J Transl Med. 2012;10:205.
14. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711.
15. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293–299.
16. Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21:125–133.
17. Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment:a pitch for multiple players. Front Oncol. 2013;3:90.
18. Brzostek J, Gascoigne NRJ, Rybakin V. Cell type-specific regulation of immunological synapse dynamics by B7 ligand recognition. Front Immunol. 2016;7:24.
19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.•• A seminal manuscript on the mechanisms of action of checkpoint inhibitors as a new potential weapon against different cancer types.
20. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3:999–1005.
21. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, et al. Immune system:a double-edged sword in cancer. Inflamm Res. 2013;62:823–834.
22. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 2002;99:3302–3309.
23. + T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother. 2011;60:1473–1484.
24. Gerrard TL, Cohen DJ, Kaplan AM. Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst. 1981;66:483–488.
25. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer:tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–992. discussion 992–993.
26. Pagès F, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human tumors:a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–1102.
27. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity:a new immunoregulatory axis. Trends Immunol. 2007;28:491–496.
28. Pesce S, Greppi M, Tabellini G, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1:A phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335–346.e3.
29. Schwaab T, Weiss JE, Schned AR, et al. Dendritic cell infiltration in colon cancer. J Immunother. 2001;24:130–137.
30. Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28:4531–4538.
31. Erdman SE, Sohn JJ, Rao VP, et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 2005;65:3998–4004.
32. Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression:role and therapeutic targeting. Vaccines. 2016;4(3):28.
33. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells:more of the same or a division of labor? Immunity. 2009;30:626–635.
34. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–192.
35. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas:the paradox of colorectal cancer. Cancer Immunol Immunother. 2011;60:909–918.
36. Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216–225.
37. Shi Y, Hu G, Su J, et al. Mesenchymal stem cells:a new strategy for immunosuppression and tissue repair. Cell Res. 2010;20:510–518.
38. O’Malley G, Heijltjes M, Houston AM, et al. Mesenchymal stromal cells (MSCs) and colorectal cancer - a troublesome twosome for the anti-tumour immune response? Oncotarget. 2016;7(37):60752–60774.
39. Glenn JD. Mesenchymal stem cells:emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014;6:526–539.
40. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–849.
41. Herrera M, Herrera A, Domínguez G, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104:437–444.
42. Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 2016;76:5241–5252.
43. Danelli L, Frossi B, Pucillo CE. Mast cell/MDSC a liaison immunosuppressive for tumor microenvironment. Oncoimmunology. 2015;4(4):e1001232.
44. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133–3140.
45. Noy R, Pollard JW. Tumor-associated macrophages:from mechanisms to therapy. Immunity. 2014;41:49–61.
46. Lewis CE, Harney AS, Pollard JW. The multifaceted role of perivascular macrophages in tumors. Cancer Cell. 2016;30:365.
47. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2010;4:141–154.
48. Rhee I. Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res. 2016;39(11):1588–1596.
49. Zhang X, Chen Y, Hao L, et al. Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. Cancer Lett. 2016;381:305–313.
50. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–215.
51. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1:653–661.
52. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711–719.•• A in depth analysis and a comprehensive assessment of the complex interrelation between tumor molecular features and host immune reactions.
53. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
54. Becht E, Giraldo NA, Germain C, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95–190.
55. Becht E, De Reyniès A, Giraldo NA, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:4057–4066.
56. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209.
57. Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8:327ra26.
58. Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome:1895-2015. Nat Rev Cancer. 2015;15:181–194.
59. Kudryavtseva AV, Lipatova AV, Zaretsky AR, et al. Important molecular genetic markers of colorectal cancer. Oncotarget. 2016;7:53959–53983.
60. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.
61. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep. 2015;3:269–276.
62. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer:implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365–16385.
63. Lin EI, Tseng L-H, Gocke CD, et al. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget. 2015;6:42334–42344.
64. Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857–865.
65. Inaguma S, Lasota J, Wang Z, et al. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol. 2017;30:278–285.
66. Toh JWT, De Souza P, Lim SH, et al. The potential value of immunotherapy in colorectal cancers:review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. 2016;15(4):285–291.
67. Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H):checkMate-142 interim results. J Clin Oncol. 2016;34.
68. Kim JH, Park HE, Cho N-Y, et al. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115:490–496.
69. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5:16–18.
70. Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2016;0:1–11.
71. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
72. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
73. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.•• The first fully published evidence for the use of PD-1 inhibitors in MSI-H gastrointestinal malignancies.
74. Study of pembrolizumab (MK-3475) vs standard therapy in participants with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (MK-3475-177/KEYNOTE-177) - full text view - ClinicalTrials.gov. NCT02563002.
75. A study to investigate efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy versus regorafenib in participants with metastatic colorectal adenocarcinoma - full text view - ClinicalTrials.gov. NCT02788279.
76. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
77. Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34.
78. Schmoll H-J, Wittig B, Arnold D, et al. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy:a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–1624.
79. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
80. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44.
81. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829.
82. Hou W, Sampath P, Rojas JJ, et al. Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer Cell. 2016;30:108–119.
83. Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer:challenges and prospective. World J Gastroenterol. 2016;22:6362–6372.
84. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
85. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma:2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–1568.
86. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139–148.
87. Wang D, DuBois RN. The role of prostaglandin E(2) in tumor-associated immunosuppression. Trends Mol Med. 2016;22:1–3.
88. Zelenay S, Reis E, Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology. 2016;5:e1123370.
89. O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy:possible therapeutic targets? Br J Pharmacol. 2015;172:5239–5250.
90. Uddin MJ, Crews BC, Xu S, et al. Antitumor activity of cytotoxic cyclooxygenase-2 inhibitors. ACS Chem Biol. 2016;11(11):3052–3060.
91. Zelenay S, Van der Veen AG, Böttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257–1270.
92. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.• A novel guideline suggesting how to evaluate response in solid tumors when using immunotherapy.
93. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents:focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12:57–75.
94. Rayner E, Van Gool IC, Palles C, et al. A panoply of errors:polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16:71–81.
95. Koopman M, Kortman GAM, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–273.
96. Lynch D, Murphy A. The emerging role of immunotherapy in colorectal cancer. Ann Transl Med. 2016;4:305.
97. Singh PP, Sharma PK, Krishnan G, et al. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep. 2015;3:289–297.